IP Library Granted Patent US 7,456,204
Granted Patent B2
US 7,456,204 · App. 10/560,771 · Granted Nov 25, 2008

Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,204
App. No.
10/560,771
Granted
Nov 25, 2008
Kind
B2
Abstract

The present invention is directed to novel cyclohexylglycine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Claims (68)

1. A compound of structural formula I:

wherein:

each n is independently 0, 1, 2, or 3;

W is selected from the group consisting of CH 2 , CHF, and CF 2 ;

X is selected from the group consisting of S, S(O), S(O) 2 , CH 2 , CHF, and CF 2 ;

Y and Z are each independently selected from the group consisting of O, S, N, and NR 7 , with the proviso that at least one of Y and Z is N;

R 1 is hydrogen or cyano;

R 2 is selected from the group consisting of

hydrogen,

halogen,

cyano,

hydroxy,

C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens,

C 1-6 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

(CH 2 ) n —COOH,

(CH 2 ) n —COOC 1-6 alkyl,

(CH 2 ) n —CONR 3 R 4 ,

(CH 2 ) n —NR 3 R 4 ,

(CH 2 ) n —NR 6 SO 2 R 5 ,

(CH 2 ) n —NR 6 CONR 3 R 4 ,

(CH 2 ) n —NR 6 COR 6 ,

(CH 2 ) n —NR 6 CO 2 R 5 ,

(CH 2 ) n -aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, C 3-6 cycloalkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

wherein any methylene (CH 2 ) carbon atom in R 2 is independently unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and

C 1-4 alkyl unsubstituted or substituted with one to five halogens;

R 3 and R 4 are independently selected from the group consisting of

hydrogen,

(CH 2 ) n -phenyl,

(CH 2 ) n —C 3-6 cycloalkyl, and

C 1-6 alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; or

R 3 and R 4 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and

C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

each R 5 is independently selected from the group consisting of (CH 2 ) n -phenyl, (CH 2 ) n —C 3-6 cycloalkyl, and C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene (CH 2 ) carbon atom in R 5 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1-4 alkyl unsubstituted or substituted with one to five halogens;

each R 6 is hydrogen or R 5 ; and

R 7 is selected from the group consisting of

hydrogen,

(CH 2 ) n -phenyl,

(CH 2 ) n —C 3-6 cycloalkyl, and

C 1-6 alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens.

2. The compound of claim 1 wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula IIa:

3. The compound of claim 1 of structural formula IIb:

4. The compound of claim 3 wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

5. The compound of claim 3 wherein the carbon atom marked with an * has the stereochemical configured as depicted in formula IIc:

and wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

6. The compound of claim 1 of structural formula Id:

7. The compound of claim 6 wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

8. The compound of claim 6 wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula IIe:

wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

9. The compound of claim 1 of structural formula IIf:

10. The compound of claim 9 wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

11. The compound of claim 9 wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula IIg:

wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

12. The compound of claim 1 of structural formula IIh:

13. The compound of claim 12 wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

14. The compound of claim 12 wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula IIi:

wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

15. The compound of claim 1 of structural formula IIj:

16. The compound of claim 15 wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

17. The compound of claim 15 wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula IIk:

wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

18. The compound of claim 1 of structural formula IIl:

19. The compound of claim 18 wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

20. The compound of claim 18 wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula IIm:

wherein X is CH 2 , CHF, or CF 2 and R 1 is hydrogen.

21. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.

22. A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of claim 1 .

Assignments (5)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 29, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023870/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2006
From: EDMONDSON, SCOTT D.; MASTRACCHIO, ANTHONY; PARMEE, EMMA R.
To: MERCK & CO., INC.
Reel/Frame 017793/0155 →